[go: up one dir, main page]

MXPA04003298A - Compuestos de piperidina como antagonistas muscarinicos. - Google Patents

Compuestos de piperidina como antagonistas muscarinicos.

Info

Publication number
MXPA04003298A
MXPA04003298A MXPA04003298A MXPA04003298A MXPA04003298A MX PA04003298 A MXPA04003298 A MX PA04003298A MX PA04003298 A MXPA04003298 A MX PA04003298A MX PA04003298 A MXPA04003298 A MX PA04003298A MX PA04003298 A MXPA04003298 A MX PA04003298A
Authority
MX
Mexico
Prior art keywords
piperidine compounds
muscarinic antagonists
compounds
methods
well
Prior art date
Application number
MXPA04003298A
Other languages
English (en)
Inventor
Samuel Chackalamannil
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04003298A publication Critical patent/MXPA04003298A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion describe compuestos, los cuales son antagonistas novedosos del receptor muscarinico, asi como metodos para preparar dichos compuestos; en otra modalidad, la invencion, describe composiciones farmaceuticas que comprenden dichos antagonistas de recetor muscarinico asi como metodos para utilizarlos para tratar trastornos cognitivos tales como enfermedad de Alzheimer.
MXPA04003298A 2001-10-10 2002-10-08 Compuestos de piperidina como antagonistas muscarinicos. MXPA04003298A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32835601P 2001-10-10 2001-10-10
PCT/US2002/032199 WO2003031412A1 (en) 2001-10-10 2002-10-08 Piperidine compounds as muscarinic antagonists

Publications (1)

Publication Number Publication Date
MXPA04003298A true MXPA04003298A (es) 2004-07-23

Family

ID=23280651

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003298A MXPA04003298A (es) 2001-10-10 2002-10-08 Compuestos de piperidina como antagonistas muscarinicos.

Country Status (10)

Country Link
US (1) US6831089B2 (es)
EP (1) EP1434766B1 (es)
JP (2) JP2005506339A (es)
CN (1) CN1301972C (es)
AT (1) ATE334965T1 (es)
CA (1) CA2462861A1 (es)
DE (1) DE60213629T2 (es)
ES (1) ES2269774T3 (es)
MX (1) MXPA04003298A (es)
WO (1) WO2003031412A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2007016183A (es) 2005-06-14 2008-03-10 Schering Corp Preparacion y uso de compuestos como inhibidores de proteasas.
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
EP2194047A1 (en) 2005-06-14 2010-06-09 Schering Corporation Preparation and use of aspartyl protease inhibitors
AR054617A1 (es) 2005-06-14 2007-07-04 Schering Corp Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden
US7759353B2 (en) 2005-06-14 2010-07-20 Schering Corporation Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
MX2009006228A (es) 2006-12-12 2009-06-22 Schering Corp Inhibidores de aspartil proteasa.
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
JP2011506461A (ja) 2007-12-11 2011-03-03 シェーリング コーポレイション γ−セクレターゼモジュレーター
CA2742486A1 (en) 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
TW201034666A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
EP2379566A2 (en) 2008-12-22 2011-10-26 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443121A2 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
EP2443119A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
US20110281853A1 (en) 2010-05-12 2011-11-17 Rishi Arora Compositions and methods for treating or preventing atrial fibrillation
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
CN1167682C (zh) * 1999-09-22 2004-09-22 先灵公司 毒蕈碱拮抗剂
US6294554B1 (en) * 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
JP2009155350A (ja) 2009-07-16
JP2005506339A (ja) 2005-03-03
DE60213629D1 (de) 2006-09-14
EP1434766B1 (en) 2006-08-02
ATE334965T1 (de) 2006-08-15
CN1568313A (zh) 2005-01-19
US20030207917A1 (en) 2003-11-06
CN1301972C (zh) 2007-02-28
US6831089B2 (en) 2004-12-14
EP1434766A1 (en) 2004-07-07
CA2462861A1 (en) 2003-04-17
ES2269774T3 (es) 2007-04-01
DE60213629T2 (de) 2007-10-18
WO2003031412A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
TW200407305A (en) Novel compounds
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2003028641A3 (en) Mch receptor antagonists
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
MXPA04000625A (es) Piperidinas sustituidas como moduladores del receptor de melanocortina.
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE60032249D1 (de) AMINO-SUBSTITUIERTE PYRAZOLOi1,5-Aö-1,5-PYRIMIDINE UND PYRAZOLOi1,5-Aö-1,3,5-TRIAZINE
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
IL161157A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
MY140835A (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
MY149422A (en) 5-(arylsulfonyl)-pyrazolopiperidines
TW200514781A (en) Novel compounds
DE60226906D1 (de) 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
TW200510378A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
SI1673354T1 (sl) Arilindenopiridini in arilindenopirimidini in njihova uporaba kot antagonisti adenozinskih A2a-receptorjev
BR0211140A (pt) Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht